- ISIN
- US7473241013
- CUSIP
- 747324101
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Oct 8, 2021
Highlights
- Market Cap
- $107.90M
- Enterprise Value
- $120.67M
- EPS (TTM)
- -$1.31
- Total Revenue (TTM)
- $13.86M
- Gross Profit (TTM)
- $13.83M
- EBITDA (TTM)
- -$79.98M
- Year Range
- $0.97 - $5.55
- Target Price
- $6.33
- ROA (TTM)
- -127.12%
- ROE (TTM)
- -261.40%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
PYXS Performance Chart
Pyxis Oncology, Inc. (PYXS) is up 47.8% since the beginning of the year. At $2 per share, PYXS is trading 69.4% below its 52-week high of $6.
Loading charts...
Returns By Period
Pyxis Oncology, Inc. (PYXS) has returned 47.83% so far this year and 28.79% over the past 12 months.
Pyxis Oncology, Inc.
- 1D
- -0.58%
- 1M
- -3.41%
- YTD
- 47.83%
- 6M
- -63.04%
- 1Y
- 28.79%
- 3Y*
- -20.08%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
PYXS Monthly Returns History
Based on dividend-adjusted daily data since Oct 8, 2021, PYXS's average daily return is +0.03%, while the average monthly return is +1.34%. At this rate, an investment would double in approximately 4.3 years.
Historically, 44% of months were positive and 56% were negative. The best month was Jan 2024 with a return of +111.7%, while the worst month was Dec 2025 at -77.8%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.
On a daily basis, PYXS closed higher 45% of trading days. The best single day was Mar 28, 2023 with a return of +42.6%, while the worst single day was Dec 18, 2025 at -48.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 26.09% | 1.38% | -0.68% | 16.44% | 5.88% | -5.56% | 47.83% | ||||||
| 2025 | 0.64% | -24.20% | -17.66% | 12.26% | 10.00% | -9.09% | 1.82% | 14.29% | 73.44% | 60.36% | 45.79% | -77.84% | -26.28% |
| 2024 | 111.67% | 66.93% | -33.02% | 4.46% | -15.96% | -11.50% | 18.43% | -3.32% | -3.17% | -3.00% | -43.54% | -22.39% | -13.33% |
| 2023 | 16.42% | 45.51% | 76.65% | -26.43% | 9.15% | -20.50% | 0.78% | -15.50% | -8.72% | -16.08% | -4.79% | 13.21% | 34.33% |
| 2022 | -13.04% | -36.27% | -33.55% | -39.36% | 0.82% | -3.64% | 11.34% | -2.26% | -23.94% | -5.08% | -22.46% | -7.59% | -87.78% |
| 2021 | 1.06% | -4.27% | -14.10% | -16.89% |
Benchmark Metrics
Pyxis Oncology, Inc. has an annualized alpha of -6.41%, beta of 1.14, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since October 11, 2021.
- This stock participated in 242.40% of S&P 500 Index downside but only 134.33% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -6.41%
- Beta
- 1.14
- R²
- 0.04
- Upside Capture
- 134.33%
- Downside Capture
- 242.40%
Return for Risk
Risk / Return Rank
PYXS ranks 54 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Pyxis Oncology, Inc. (PYXS) and compare them to S&P 500 Index.
| PYXS | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.25 | 2.24 | -2.00 |
Sortino ratioReturn per unit of downside risk | 1.25 | 3.07 | -1.83 |
Omega ratioGain probability vs. loss probability | 1.18 | 1.41 | -0.23 |
Calmar ratioReturn relative to maximum drawdown | 0.36 | 2.93 | -2.57 |
Martin ratioReturn relative to average drawdown | 0.60 | 13.52 | -12.92 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Pyxis Oncology, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Pyxis Oncology, Inc. was 93.57%, occurring on Apr 8, 2025. The portfolio has not yet recovered.
The current Pyxis Oncology, Inc. drawdown is 87.54%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -93.57%Apr 2025 | 3y 5mo | — | 4y 7moNov 2021 - now |
2021 correction2021 | -12.95%Oct 2021 | 8d | 9d | 17dOct 2021 - Oct 2021 |
2021 pullback2021 | -1.05%Nov 2021 | 0s | 2d | 2dNov 2021 - Nov 2021 |
Drawdown Indicators
| PYXS | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.57% | -56.78% | -36.79% |
Max Drawdown (1Y)Largest decline over 1 year | -80.15% | -9.10% | -71.05% |
Max Drawdown (3Y)Largest decline over 3 years | -86.69% | -18.90% | -67.79% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -87.54% | -0.74% | -86.80% |
Average DrawdownAverage peak-to-trough decline | -76.77% | -10.72% | -66.05% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 47.87% | 1.97% | +45.90% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Pyxis Oncology, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Pyxis Oncology, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for PYXS relative to other companies in the Biotechnology industry. Currently, PYXS has a P/S ratio of 7.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for PYXS in comparison with other companies in the Biotechnology industry. Currently, PYXS has a P/B value of 3.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with PYXS
Add Pyxis Oncology, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with PYXS